Peptilogics
Peptilogics is a biotech company using its Nautilus AI platform to design peptide therapeutics, like its anti-infective candidate PLG0206.
Secondary Market Price
How Peptilogics Measures Up
To help you manage your Peptilogics equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series B2
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Peptilogics's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Peptilogics Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Peptilogics's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Peptilogics is a clinical-stage biotechnology company that develops peptide therapeutics for serious diseases by combining machine learning with peptide biology. The company's lead product, PLG0206, is a broad-spectrum anti-infective peptide currently in clinical trials for the treatment of prosthetic joint infection. Its Nautilus AI platform enables predictive peptide design to create therapeutics with drug-like properties. Founded in 2013 by Jonathan Steckbeck, the Pittsburgh-based company has since advanced its lead candidate into clinical studies.
The company's future plans involve scaling its drug design approach to engineer a new generation of peptide therapeutics, with a continued focus on the clinical development of PLG0206. A key recent milestone was a Series B funding round on November 16, 2025, which raised $78.0 million. Notable investors in the round included Thiel Bio and Founders Fund, providing significant capital to support the company's research and development efforts.
- Presight Capital
- Thiel Bio
- Founders Fund
- AMR Action Fund
- Narya Capital
- Beyond Ventures
- Peter Thiel
- CARB-X
- Cystic Fibrosis Foundation
- Co-Founder, Jonathan Steckbeck
- Co-Founder, Ron Montelaro
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Peptilogics worth joining?
Deciding whether to join any startup requires a careful analysis of its growth prospects and the potential value of your equity compensation. Platforms like Prospect can help you model different outcomes for your equity and make a more informed career decision.
What should I do with my Peptilogics stock?
The right strategy for your Peptilogics stock depends on your personal financial goals, risk tolerance, and tax situation. Tools like Prospect can build a customized plan for exercising options and selling shares to help you maximize your potential returns.
Can you sell Peptilogics stock?
As a private company, selling Peptilogics stock is typically restricted to company-approved events like tender offers or through secondary markets. Platforms such as Prospect offer tools to help you navigate these sales and determine which shares are most tax-optimal to sell.
How can I find the value of my Peptilogics stock?
The official value of private stock is determined by a 409A valuation, which sets the fair market value for tax purposes. To project the potential future value, you can use services like Prospect, which apply machine learning models to various data points to forecast a range of likely outcomes.
What is Peptilogics's equity worth?
The total value of Peptilogics's equity is based on its most recent valuation, typically set during a funding round. Your personal equity stake's future worth can be estimated using tools like Prospect, which analyze company data to project its value under various scenarios.
What is Peptilogics's stock ticker symbol?
Peptilogics is a private company, so it does not have a stock ticker symbol. Ticker symbols are assigned to companies only when they become publicly traded on a stock exchange like the NYSE or NASDAQ.
Can I buy or sell Peptilogics stock?
As Peptilogics is a private company, buying its stock is generally restricted to accredited investors or employees receiving equity compensation. Selling shares is also limited and typically only possible during specific liquidity events, such as a tender offer, which platforms like Prospect can help you navigate.
What is the criteria to buy or invest in Peptilogics stock?
Investing in a private company like Peptilogics is typically reserved for venture capital firms and accredited investors who meet specific wealth or income requirements. For employees, the primary way to "invest" is by exercising their stock options as part of their compensation package.
